期刊文献+

嵌合抗原受体T细胞产品医保创新支付模式研究 被引量:1

Research on innovative payment mode of medical insurance for chimeric antigen receptor T cell products
原文传递
导出
摘要 作为新型肿瘤免疫治疗药品,嵌合抗原受体T细胞(chimeric antigen receptor T cell,CAR-T)上市时间短、定价高,临床用量难以精准预测,目前尚未纳入我国医保目录。该文在分析CAR-T产品医保支付难点的基础上,结合我国医保管理体制,构建创新支付4步走结算模式,并从实操层面提出“量价挂钩—商保协同—先行谈判”3项操作要点,确保创新支付落地应用,降低医保基金支出风险,提高CAR-T产品可及性。 As a novel cancer immunotherapy with high market price,chimeric antigen receptor T cell(CAR-T) has not been marketed for a long time,and its clinical usage is difficult to predict precisely.Currently it has not been included in the National Reimbursement Drug List (NRDL).Based on the analysis of the difficulties in reimbursing CAR-T products,combining the medical insurance management system in China,the paper proposed to establish a four-step settlement mode for CAR-T products,and brought forward three key points of “coordination between price and volume-collaborating with commercial health insurance-advance negotiation” from the practical side,to ensure the implementation of the innovative payment mode,reduce the risk of medical insurance fund expenditure,and improve the accessibility of CAR-T products.
作者 刘丹妮 丁锦希 李佳明 李伟 LIU Danni;DING Jinxi;LI Jiaming;LI Wei(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 211198,Jiangsu Province,China;Pharmaceutical Market Access Policy Research Center,China Pharmaceutical University,Nanjing 211198,Jiangsu Province,China)
出处 《世界临床药物》 2022年第4期369-376,共8页 World Clinical Drug
基金 中国药科大学“双一流”学科创新团队建设项目(CPU2018GY4)。
关键词 嵌合抗原受体T细胞(CAR-T) 创新支付 量价协议 chimeric antigen receptor T cell(CAR-T) innovative payment price-volume agreement
  • 引文网络
  • 相关文献

参考文献6

二级参考文献27

  • 1石远凯,刘鹏,杨晟,韩晓红,何小慧,艾斌,秦燕,李博,黄鼎智,张长弓,孙燕.注射用聚乙二醇化重组人粒细胞集落刺激因子I期临床耐受性试验[J].癌症,2006,25(4):495-500. 被引量:31
  • 2石远凯,何小慧,杨晟,王华庆,江泽飞,朱允中,克晓燕,张阳,刘云鹏,张伟京,王昭,石庆芝,谢晓冬,张贺龙,王杰军,罗德云,郑青山,孙瑞元.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少症的多中心随机对照Ⅱ期临床研究[J].中华医学杂志,2006,86(48):3414-3419. 被引量:43
  • 3国务院办公厅关于完善公立医院药品集中采购工作的指导意见[EB/OL].[2015-02-28].http://www.gov.cn/zhengce/content/2015-02/28/content9502.htm.
  • 4何建志.全民健康保险价量协议法律问题分析[J].台大法学论丛,2014,43(2):381-417.
  • 5ADAMSKI J, GODMAN B, OFIERSKA-SUJKOWSKA G, et al. Risk sharing arrangements for pharmaceuticals: potential consider- ations and recommendations for European payers[ J]. BMC Health Serv Res, 2010, 10(1) : 153.
  • 6YANG WW, PWU RF. International experiences of risk sharing mechanism[ J]. Reg Med News, 2013, 29 : 1 - 20.
  • 7The Listing Steps. Department of Health and Ageing [ EB/OL ]. [2014 -07 -09 1. http://www, pbs. gov. au/info/industry/list- ing/listing-steps.
  • 8卫生福利部中央健康保险署药材专区[EB/OL].[2015-06一04].http://wwwnhi.gov.tw/webdata/webdata.aspx?menu=21&menu-id=713&webdata-id=2942.
  • 9Pharmaceutical Management Agency: Annual Review 2009 [ EB/ OL]. [ 2010 - 12 - 12 ]. http://www, pharmac, govt. nz/2009/ 01/01/PHARMAC% 20Annual% 20Review% 202009. pdf.
  • 10胡善联.深化医药卫生体制改革的若干问题探讨[J].卫生经济研究,2010,27(1):5-7. 被引量:8

共引文献156

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部